Department of Medicinal Chemistry, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan.
J Med Chem. 2011 Dec 8;54(23):7962-73. doi: 10.1021/jm200870n. Epub 2011 Nov 9.
The design and evaluation of low molecular weight peptide-based severe acute respiratory syndrome (SARS) chymotrypsin-like protease (3CL) protease inhibitors are described. A substrate-based peptide aldehyde was selected as a starting compound, and optimum side-chain structures were determined, based on a comparison of inhibitory activities with Michael type inhibitors. For the efficient screening of peptide aldehydes containing a specific C-terminal residue, a new approach employing thioacetal to aldehyde conversion mediated by N-bromosuccinimide was devised. Structural optimization was carried out based on X-ray crystallographic analyses of the R188I SARS 3CL protease in a complex with each inhibitor to provide a tetrapeptide aldehyde with an IC(50) value of 98 nM. The resulting compound carried no substrate sequence, except for a P(3) site directed toward the outside of the protease. X-ray crystallography provided insights into the protein-ligand interactions.
本文描述了基于低分子量肽的严重急性呼吸综合征(SARS)冠状病毒主蛋白酶(3CLpro)蛋白酶抑制剂的设计与评价。以基于底物的肽醛为起始化合物,通过与迈克尔型抑制剂的抑制活性比较,确定了最佳的侧链结构。为了高效筛选含有特定 C 末端残基的肽醛,设计了一种新方法,采用 N-溴代丁二酰亚胺介导的硫缩醛到醛的转化。基于 SARS 3CLpro 与每个抑制剂形成的复合物的 X 射线晶体结构分析进行结构优化,得到了一种 IC50 值为 98 nM 的四肽醛。所得化合物除了 P3 位朝向蛋白酶外部的序列外,不含有任何底物序列。X 射线晶体学提供了对蛋白-配体相互作用的深入了解。